The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location
Open accessAbstract
As the enhanced permeation and retention (EPR) effect continues to be a controversial topic in nanomedicine, we sought to examine EPR as a function of nanoparticle size, tumor model, and tumor location, while also evaluating tumors for EPR mediating factors such as microvessel density, vascular permeability, lymphatics, stromal content, and tumor-associated immune cells. Tumor accumulation was evaluated for 55 × 60, 80 × 180, and 80 × 320 nm PRINT particles in four subcutaneous flank tumor models (SKOV3 human ovarian, 344SQ murine nonsmall cell lung, A549 human nonsmall cell lung, and A431 human epidermoid cancer). Each tumor model revealed specific particle accumulation trends with evident particle size dependence. Immuno-histochemistry staining revealed differences in tumor microvessel densities that correlated with overall tumor accumulation. Immunofluorescence images displayed size-mediated tumor penetration with signal from the larger particles concentrated close to the blood vessels, while signal from the smaller particle was observed throughout the tissue. Differences were also observed for the 55 × 60 nm particle tumor penetration across flank tumor models as a function of stromal content. The 55 × 60 nm particles were further evaluated in three orthotopic, metastatic tumor models (344SQ, A549, and SKOV3), revealing preferential accumulation in primary tumors and metastases over healthy tissue. Moreover, we observed higher tumor accumulation in the orthotopic lung cancer models than in the flank lung cancer models, whereas tumor accumulation was constant for both orthotopic and flank ovarian cancer models, further demonstrating the variability in the EPR effect as a function of tumor model and location.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Self-citationDrug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
Sykes, E. A., Chen, J., Zheng, G., & Chan, W. C. W. (2014) · ACS Nano · doi:10.1021/nn500299p · Cited by 635
Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P., Jones, S. W., Luft, J. C., Napier, M., Bear, J. E., & DeSimone, J. M. (2012) · Nano Letters · doi:10.1021/nl302638g · Cited by 606
Self-citationChauhan, V. P., Popović, Z., Chen, O., Cui, J., Fukumura, D., Bawendi, M. G., & Jain, R. K. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201104449 · Cited by 473
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060929 · Cited by 468
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441
Black, K. C. L., Wang, Y., Luehmann, H. P., Cai, X., Xing, W., Pang, B., Zhao, Y., Cutler, C. S., Wang, L. V., Liu, Y., et al. (2014) · ACS Nano · doi:10.1021/nn406258m · Cited by 365
Miller, M. A., Gadde, S., Pfirschke, C., Engblom, C., Sprachman, M. M., Kohler, R. H., Yang, K. S., Laughney, A. M., Wojtkiewicz, G., Kamaly, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6522 · Cited by 347
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Superior Penetration and Retention Behavior of 50 nm Gold Nanoparticles in Tumors
Huo, S., Ma, H., Huang, K., Liu, J., Wei, T., Jin, S., Zhang, J., He, S., & Liang, X.-J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2071 · Cited by 337
A Nanoparticle Size Series for In Vivo Fluorescence Imaging
Popović, Z., Liu, W., Chauhan, V. P., Lee, J., Wong, C., Greytak, A. B., Insin, N., Nocera, D. G., Fukumura, D., Jain, R. K., et al. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201003142 · Cited by 332
Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines
Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., Hermanns-Sachweh, B., Pechar, M., Ulbrich, K., Hennink, W. E., et al. (2014) · Nano Letters · doi:10.1021/nl404391r · Cited by 317
Orthotopic models of cancer for preclinical drug evaluation
Bibby, M. C. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.021 · Cited by 315
Cancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Smith, B. R., Kempen, P., Bouley, D., Xu, A., Liu, Z., Melosh, N., Dai, H., Sinclair, R., & Gambhir, S. S. (2012) · Nano Letters · doi:10.1021/nl204175t · Cited by 212
Onn, A., Isobe, T., Itasaka, S., Wu, W., O’Reilly, M. S., Hong, W. K., Fidler, I. J., & Herbst, R. S. (2003) · PubMed · Cited by 182
Dawidczyk, C. M., Russell, L. M., & Searson, P. C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00069 · Cited by 164
Schädlich, A., Caysa, H., Mueller, T., Tenambergen, F., Rose, C., Göpferich, A., Kuntsche, J., & Mäder, K. (2011) · ACS Nano · doi:10.1021/nn2026353 · Cited by 161
Evaluation of nanomedicines: stick to the basics
McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126
Harrington, K. J., Rowlinson‐Busza, G., Syrigos, K. N., Abra, R. M., Uster, P. S., Peters, A. M., & Stewart, J. S. W. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1320 · Cited by 91
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs
Song, G. K., Wu, H., Yoshino, K., & Zamboni, W. C. (2012) · Journal of Liposome Research · doi:10.3109/08982104.2012.655285 · Cited by 90
Self-citationKarathanasis, E., Chan, L. W., Karumbaiah, L., McNeeley, K. M., D’Orsi, C. J., Annapragada, A., Sechopoulos, I., & Bellamkonda, R. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005843 · Cited by 74
Duncan, R., Sat-Klopsch, Y.-N., Burger, A. M., Bibby, M. C., Fiebig, H., & Sausville, E. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2209-7 · Cited by 61
The Passive Targeting of Polymeric Micelles in Various Types and Sizes of Tumor Models
Xiao, K., Luo, J., Li, Y., et al. (2010) · Nanoscience and Nanotechnology Letters · doi:10.1166/nnl.2010.1059 · Cited by 23
Patterns of Vasculature in Mouse Models of Lung Cancer Are Dependent on Location
Vilalta, M., Hughes, N. P., von Eyben, R., Giaccia, A. J., & Graves, E. E. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1010-5 · Cited by 21
Cited by
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 444
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Hu, C., Cun, X., Ruan, S., Liu, R., Xiao, W., Yang, X., Yang, Y., Yang, C., & Gao, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.046 · Cited by 276
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Metadata
- Authors
- Perry, J. L., Reuter, K. G., Luft, J. C., Pecot, C. V., Zamboni, W., & DeSimone, J. M.
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-04-11
- Volume
- 17
- Issue
- 5
- Pages
- 2879-2886
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2595421589
- Cited by
- 255
- References
- 37
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.